Fifty-five patients with winter seasonal affective disorder (SAD) were treated with a light visor, a newly developed ,mabie light-delivery system, in a controlled parallel agn. A dim (400 lux) visor was compared with a Wight (6000 lux) visor for either 30 or 60 minutes in the .oming for 1 week. Response rates for these two IrtItments were 36% and 56%, respectively; the duration � treatment sessions did not affect outcome. There was lEY WORDS: Seasonal affective disorder; Phototherapy; light; Circadian rhythms; Seasons; Depression
no evidence that the brighter visor was superior in efficacy to the dimmer one. Significantly greater relapse occurred following withdrawal of the dimmer visor. Alternative explanations for these findings are that the light visor is acting as a placebo or that it is equally effective over a wide range of intensities.
fNeuropsychopharmacology 8: 151-160, 1993J of light boxes, which some patients have found con straining. To obviate this inconvenience, we developed a portable head-mounted light-delivery system (Rosen thal and Wehr, unpublished observation 1988; Brainard and Benson, unpublished observation 1988; Stewart et al. 1990 ; patent: #4,911,166, a portable light-delivery system). We tested the efficacy of this device by com paring light visors of two different intensities, one above and the other below the putative threshold for therapeu tic efficacy, as estimated from the results of earlier studies with conventional light boxes (Checkiey et al. 1986; Isaacs et al. 1988; James et al. 1985; Rosenthal et al. 1984 Wirz-Justice et al. 1986 ). We hypothe sized that the brighter visor would produce antidepres sant effects superior to those of the dimmer one. The study was conducted at three sites: the National Insti tute of Mental Health (NIMH), Bethesda, Maryland; Providence Hospital, Seattle, Washington; and Brook side Hospital, Nashua, New Hampshire. The present report documents the outcome of this study and dis cusses its implications.
MATERIALS AND METHODS

Subjects
Participants in the study were 55 adult volunteers recruited via community referral channels and the lo cal news media. To be included, subjects had to meet the SAD criteria of Rosenthal et al. (1984) and the DSM III-R criteria for a lifetime history of major depression (Spitzer et al. 1989) . One exception to the criteria of Rosenthal et aI. (1984) w-as the inclusion of patients with a past history of other Axis I psychiatric disorders, provided there was no active evidence of the disorder at the time of evaluation. Patients were required to be in reasonably good physical health as determined by history, physical examination, electrocardiogram, rou tine bloodwork, and urinalysis. Patients with retinal dis eases or cataracts, untreated hypothyroidism, or any serious medical conditions were excluded.
Taking medications was not in itself an exclusion ary criterion provided that patients agreed to maintain their medications at &xed dosages throughout the study. Shift-workers and others who were unable to maintain consistent sleep schedules throughout the study period were excluded. Those patients who had been receiving traditional light therapy were eligible, provided they discontinued that therapy for at least 2 weeks before entering the study. All subjects provided written informed consent.
The Light Visor
The head-mounted light-therapy device or ''light visor" was developed collaboratively by investigators at the NIMH (N. E.R. and T.A. W .), the Biomedical Engineer ing and Instrumentation Program of the National In stitutes of Health (Stephen B. Leighton, Sc.D.), and Jefferson Medical College (G.CB.) and was supplied by Bio-Brite, Inc, Bethesda, Maryland. The visor con sists of two light sources, one directed toward each eye, Figure 1 . Illustration of the light visor. NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.2 each set in a plastic hemisphere with a highly reflective metal coating behind translucent diffusing and mylar hlters, which spread the light over a circular surface area approximately 7 cm in diameter (see Fig. 1 ). The visor is powered by a portable rechargeable battery source. The light is emitted from miniature 2.6-watt krypton incandescent bulbs and contains virtually no ultravio· let rays after it has passed through the mylar fIlter. The spectral power of the visor was measured with a McPherson monochromator with a Hamamatsu pho tomultiplier and solid-state amplifler. This equipment was calibrated with a model 22A 200-watt quartz· tungsten lamp (Optronic Laboratories, Inc.) traceable to NIST (see Fig. 2 ). The metal hemispheres reflect the light toward the eyes, thereby maximizing the efficiency of the system. The diffusing fIlters help reduce the con· centration of brightness in the center of the light. emitting surface. When the visor is worn as intended, the light-emitting area occupies the upper half of the visual oelds allowing the wearer to see his surround· ings while receiving treatment.
To test the efficacy of the visor, we chose two diff er· ent illuminances, one brighter (approximately 6000 lux) and one dimmer (approximately 400 lux). The ill umi· nance of the bright visor was chosen because it falls in the range of previously active light-treatment condi tions, and the illuminance of the dim visor falls in the range of light-treatment conditions found previously to be relatively ineffective 
Study Design and Procedures
We employed a randomized single-blind parallel lreatment design in which we compared bright and dim visors over three phases, each lasting 1 week: baseline, lreatment and withdrawal. During the baseline period, patients were asked to adhere to consistent sleep-wake schedules because of the known antidepressant effects of sleep deprivation in nonseasonal depressives and the poss ibility that SAD patients might be similarly affected.
In additi on, we asked patients to keep a daily log of wake-up times since sleep deprivation has been reported to have maximum antidepressant effects in the liter part of the night (Wehr 1990 (Borkovec and Nau 1972) . We did not inform the patients that we were test ing two different visors, nor did we discuss with them our specifIc hypothesis. We told them only that we were trying to determine whether the light visor was clini cally effective and asked them not to discuss the study with any other participants. We requested that patients maintain their ambient lighting at the same level dur ing their treatment sessions as it had been at that time of day during the baseline week. We asked them to re strict their movements during treatments as we were concerned that those wearing the bright visor might bump into things as a result of glare.
On the basis of earlier studies that showed that 30 minutes of treatment with 10,000 lux is effective for win ter SAD (Terman et al. 1989b) , we initially selected 60-minutes of light treatment in the morning, predicting that it would be more effective for the 6000-lux than for the 400-lux condition. We asked patients to wear their visors at a consistent time between 6:30 A.M. and 8:30
A.M. for seven consecutive mornings. Preliminary anal-"l54. N.R. Rosenthal et al. ysis of the fust 21 subjects revealed that the dim visor was yielding surprisingly good results, making it less likely that the predicted difference between groups, that is the predicted superiority of the bright over the dim visor, would be detected with the initial treatment de sign. In an attempt to elicit this predicted difference in the remaining subjects, we decreased the daily treat ment time for the remaining 31 subjects to 30 minutes, at the same time in the morning as before.
After each treatment week, we withdrew patients from light for 1 week and measured their mood once again.
No specifIC measures were taken to evaluate the effects of the light visor on the eyes since individuals with evidence of signifIcant ocular pathology were ex cluded from the study and the illuminances emitted by both visors were well below typical outdoor levels (Thorington 1985) and within recommended indoor il luminances (Kaufman and Christensen 1987) . We should note, however, that the value of such light level comparisons is limited by the fact that the light from the visor bears a hxed relation to the head and eyes and therefore cannot be as readily avoided as light emanat ing from the sky.
Dependent Variables
Mood was measured with the SIGH-SAD by raters blind to the patient's treatment status. To maximize reliability across centers, raters at all centers were given standard scoring instruction and their reliability was tested on 12 videotaped SIGH-SAD interviews of depressed patients. Reliability of raters was quite good both within and across centers (intraclass correlation = 0.98 for raters in Bethesda and Nashua and 0.95 across centers). There were hve raters at Bethesda, three at Nashua, and one at Seattle. Oinical care was pro vided by clinicians blind to which visor any particular patient received.
To estimate the amount of light actually entering the eye, we measured pupillary diameters of the pa tients in Bethesda by photographing the eye with a Po laroid camera htted with a 1:11ens (to avoid spherical Based on these initial lurninance values and using pupil-NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.2 lary sizes from subjects at the Bethesda site, rough esti· mates of retinal illuminance were made from the formula of Wyszecki and Stiles (1982) . We collected information on side effects from a standard rating form, which pa· tients completed at the end of the study.
Statistical Analysis
Hamilton To determine the association between response and retinal illuminance, correlations were performed be· tween retinal illuminance values and the change in HDRS and SIGH-SAD total scores for the Bethesda group as a whole and separately for bright-and dim· visor subgroups. In all analyses, two-tailed signifIcance levels were used. In those instances where multiple comparisons were performed, appropriate adjustments were made for the increased probability of making a Type I error.
RESULTS
Clinical and Demographic Features
The distribution of subjects across the three sites (Bethesda, Seattle, and Nashua), the two durations (60 and 30 minutes), and the two treatment conditions (bright and dim) are shown in Table 1 . Most patients were seen in Bethesda and Seattle, with approximatel y the same number seen in each of these two places. Since the 60-minute treatment condition was the hrst para· digm used, and the study in Seattle was initiated slightly after the study in Bethesda, more patients were a Each cell records the number of patients in the condition with the exception of cells that contain m;an age and standard deviations.
Includes those on antidepressants.
seen on the 3D-minute condition than on the 60-minute rondition in Seattle, whereas approximately equal num bers were treated with each duration in Bethesda. Twenty-one subjects were treated with the 60-minute ron .
dition and 34 with the 3D-minute condition. Thirty patients were treated with the bright and 25 with the dimcondition. The unequal number resulted from our iltempt to ra ndomize in a stratifted way, taking into munt medication status and prior exposure to light treatment.
Most o f the patients (84%) were women (27 of 30 mthe bright condition and 19 of 25 in the dim condi IXln). The mean age (± SO) was virtually identical for bright and dim conditions (42 ± 9.2 and 42 ± 9.1 years, respectively). Most of the patients (53 of 55) met OSM m-R criteria for major depression and only two met aiteria for bipolar depression. As can be seen in Table   1 . lO0f 55 subjects had had prior exposure to light ther-4'Y and 29 of 55 patients were medication-free through out the study. Although it was our intention to treat � numbers of these diff erent groups with bright and dimlight, more unmedicated patients were treated with the bright visor than with the dim visor (19 vs. 10), lOO ugh this difference did not reach statistical signift ance.
Effects on Mood
The mean baseline total SIGH-SAD scores (± SO) for patients who received bright-and dim-light treatment were 31.0 ± 6.6 and 31.2 ± 7.6, respectively (NS). Cor responding posttreatment scores (± SO) were 19.5 ± 11.4 and 14.2 ± 8.8, and withdrawal scores were 22.5 ± 10.1 and 28.4 ± 10.4. The mean baseline 21-item HORS scores for patients who received bright and dim light were 16.8 ± 4.3 and 17.7 ± 4.7, respectively. Cor responding posttreatment scores were 11.0 + 5.9 and 8.9 ± 5.5, and withdrawal scores were 13.2 ± 5. 5 and 16.7 ± 6.1 (see Fig. 3A and B) .
Analysis of variance with repeated measures on the 21-item HORS data showed a signiftcant time-by intensity interaction (F = 5.16, dt = 2, p < 0.01; see Fig.   3A and 3B). Post-hoc t-tests showed this effect to be due almost entirely to differences in withdrawal values that were lower after the bright-than the dim-light treat ment (t = 2.27, dt = 53, p < 0.05). Although pre-and posttreatment HORS scores were signiftcantly differ ent for both dim and bright visors (t = 7.72, dt = 24, p<O.OOl; and t = 7.25; dt = 29, p< 0.001, respectively), P ? sttreatment and withdrawal values differed sig mftcantly only for the dim (t = 5.72, dt = 24, p < 0.001), are shown for all 55 subjects treated with bright and dim vi sors before and after 1 week of treatment and after 1 week of withdrawal. There were significant time-by-condition in teractions for both measures, both largely due to the greater withdrawal effect following dim-light treatment.
but not the bright visor (t = 1. 54, df = 29). There was no interaction between duration and condition, sug gesting no difference in efficacy between the 60-minute and the 30-minute treatment conditions. Similarly, there was no signifIcant site-by-condition interaction (see Fig. 4A and B), nor any effect of a history of prior light treatment on outcome.
In evaluating the results according to the stringent response criteria of Terman et al. (1989) , [reduction of HDRS scores to � 50% of baseline and < 8]), we found a tendency for the patients to respond better to the dim than to the bright visor, although this did not reach statistical signifIcance (see Table 2 ). Thus, response rates for the dim visor were 7 of 11 (63%) and 7 of 14 (50%)
for the 60-minute and 3D-minute conditions, respec We also examined response rates by looking at SIGH-SAD total scores, which incorporate atypical symptoms scores (Rosenthal and Heffernan 1986) , and defIned as responders those individuals whose totals were reduced to less than or equal to 50% of baseline, as has previously been suggested (Eastman et al. 1989) (see Table 2 ). With this approach, we found the reo sponse rates for the dim visor to be 7 of 11 (63%) and 10 of 14 (71%) for the 60-minute and 30-minute condi· tions, respectively. Corresponding values for the bright visor were 3 of 10 (30%) and 9 of 20 (45%), respectively. tween expecting the light to improve their symp�oms "moderately" and "quite a bit. " There were no dIffer ences in expectations of the two visors and no corre�a lion between expectations (as measured on a 5-pomt gJe) an d outcome for either bright-or dim-visor treat ments.
Side effects were reported with approximately equal frequency under both visor conditions (Table 3 ).
The most commonly reported side effects were head ache, eyestrain, and fatigue, although the last was at Analysis of variance revealed no signifIcant main effects or interactions, and there was no trend toward signifIcance. 
Pupillary Measurements
At the Bethesda site, we photographed the eyes of 9 patients wearing bright visors and 10 other patients wearing dim visors, in both cases with the light sources on. The mean (± SO) pupillary area of patients wear ing the bright visor was 7. 1 ± 2.5 mm2 and of those wearing the dim visor was 12.8 ± 4.5 mm2. These were signifIcantly different (t = -3.37, df = 17, P < .01).
The estimated total luminance of a dim visor was 
0% 0%
a All values expressed as means ± SO.
'.
b Severity is rated on a scale of 0 to 3, 0 = absence of symptoms; 1 = mild; 2 = moderate, and 3 = severe.
DISCUSSION
The SAD patients treated in the present study were clin ically and demographically similar to those we have de scribed previously (Rosenthal et al. 1984; Oren and Rosenthal 1992) . The low prevalence of bipolar pa tients in this study (which stands in contrast to our ear lier reports) stems from our change in diagnostic criteria over time from the Research Diagnostic Criteria (Spit zer et al. 1978) , which have a relatively low threshold for the diagnosis of hypomania, to the DSM-III-R criteria (Spitzer et al. 1989) , which require actual dysfunction as a result of hypomania for a patient to qualify for a bipolar diagnosis.
In this fIrst clinical trial of the light visor, our hy pothesis that the bright visor would be more effective than the dim one was not borne out. There was no statistical difference in efficacy between the two visors, regardless of how such efficacy was measured, although there was a trend toward a poorer response rate for the bright visor. There is thus no evidence that the light visor was effective, when efficacy is defIned as produc ing a greater antidepressant effect than placebo. Al though analysis of the SIGH-SAD ratings showed a signifIcant interaction between phase of the study and intensity, this was not due to a difference in treatment effect but rather to a greater tendency to relapse follow ing withdrawal from the dim than the bright visor.
Insofar as there was no difference in efficacy be tween the "active," (6000-lux) and "control" (400-lux) treatments, this study does not provide any direct evi dence for a specifIc therapeutic effect of the bright vi sor. One explanation for the observed improvement in mood is that it was due entirely to a placebo effect. Al ternatively, both treatments might have been biologi cally active and might have exceeded a therapeutic threshold. These same alternative possible explanations might be invoked to account for the results of two sub sequent multicenter studies (Levitt et al. 1991; Teischer et al. 1992) , where no differences in efficacy were ob served across visor treatments of widely different in tensities. On the basis of the present study and its two successors, there is no defInitive way of deciding be tween the aforementioned competing explanations.
If the visor exerted its antidepressant effects by placebo mechanisms alone, how can this explanation be reconciled with earlier evidence that treatment with the light box was superior to placebo? One possible ex planation is that the visor delivers light to the eyes less efficiently or from a smaller proportion of the visual fIelds than the light box. Thus, Gaddy et al. (1992) found a greater degree of melatonin suppression in normal subjects exposed to 4000 lux at the surface of the cor nea when the light source was a box than when it was a visor. That fInding showed that simple measurement of corneal illumination is insufficient to predict the NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.2 effects of light on melatonin suppression. On the other hand, bright light emitted from a visor is not without biologic effects. Thus, visor light at 4000 lux can signifIcantly suppress nocturnal melatonin (Gaddy et al. 1992) and visor light at 3200 lux can signifIcantl y dampen the normal nocturnal decline in body temper· ature (Edelson et al. 1991) .
Some have argued that the antidepressant response to the light box might also be nothing more than a placebo effect and have pointed out that a defInitive placebo-controlled study of light-box therapy for SAD has yet to be done (Eastman 1990) . Notwithstanding design flaws, differential effects of "active" and "con· trol" light-box treatments have been found in several . although by no means all, light-box studies, including comparisons of light of diff erent intensities, timing and color, or exposure to diff erent parts of the body (for re· view see Terman and Terman 1991; Oren and Rosenthal 1992) . Such differential effects have not thus far been found in studies of the light visor. For this reason, there is less evidence to suggest a specifIc antidepressant effect for the light visor than for the light box.
The present study had some advantages over its predecessors. First, the number of subjects studied wal relatively large. Second, expectations were measured ahead of time and were found to be no different for the two visors being studied. Finally, the multicenter na· ture of the study decreased the likelihood that the results obtained were specifIc to a particular center. Limitations of the study included: 1) incomplete log· ging of sleep (only wake-up times were registered). leaving open the possibility that different sleep patterns in the two visor conditions might have obscured poten· tial differences in efficacy (although antidepressant effects of sleep deprivation have not yet been well demonstrated in SAD); 2) imperfect control of the am· bient lighting environment in which subjects received their light therapy; and 3) since we asked patients to remain relatively stationary during treatment ses· sions, we were unable to evaluate whether the visor per· mitted free mobility at these times.
If the antidepressant effects of the light visor were specifIc, that is, not solely a result of a placebo effect. why did we not fInd the predicted relationship between intensity and response? This same question was ad· dressed by Terman (1991) in a discussion of the pre· sentation of the subsequent light-visor study by Levitt et al. (1991) . Even though subjects were shown exactl y how we wanted them to position the visor, we had no way of knowing how well they complied with these in· structions. Small differences in positioning of a light source close to the eye could result in large differences in the amount of light entering the pupil. Further modifIcations in the amount of light entering the pupil could result from squinting, lowering the eyelids, or changes in pupillary size. Such pupillary size changes might not have been detected by our measurement at asingle point in time. Finally, we cannot rule out the poss ible confound of different retinal adaptations to diff erent light intensities. If the similarity in response rates resulting from treatment with the different visors inot entirely due to a placebo effect, specifIc explana tions for the absence of an intensity response relation ship are needed.
The response rates seen in this visor study (as defmed by the strict criteria ofTerman et al. (1989a) : that is,adecrease to < 8 on HDRS and a decrease to'::; ; 50% dbaseline) were 56% and 36% for the 400-lux and 6000-lax visors, respectively. In the later multicenter study on 105 SAD patients, Levitt et al. (1991) , reported re sponse rates (defIned only slightly differently as HDRS O,�50% of baseline) for visors of 60-lux, 600-lux, and !iOO-lux intensity to be 52%, 45%, and 50%, respec tively. In the later multicenter study on 57 patients, Teischer et al. (1992) reported response rates (HDRS <8, � 50% of baseline) for red-visor treatments of 30-�inte nsity and white-visor treatments of 600-lux in lensity to be 50% and 36%, respectively. In none of the Ihree visor studies undertaken to date were response rates signihcantly different across treatment conditions.
The response rate seen with the 400-lux visor in the present study (56%) is similar to those found in several previous studies with 2500-lux light boxes, greater than Ihosefound with previous placebo treatments or light ing conditions regarded as inactive, but less than treat ments with IO,OOO-lux light boxes (Rosenthal and Moul J9IXl; Terman 1991) . This information may be useful to clinicians face d with the decision of recommending a lreatment intervention to a patient; however, it does lilt speak to whether the light visor is acting solely as aplacebo or in a specifIc way as well.
It is cle ar that the method of ocular exposure can becritical in determining whether or not a light stimu .. will induce a specifIc effect, quite independent of lheilluminance of the stimulus. For example, Lewy et ill . (1980) found that light of 2500 lux or more was re quired to suppress nocturnal human melatonin secre1iIm. Later, however, Brainard et al. (1988) found that when they carefully controlled ocular exposure, pupil brysize, and stimulus characteristics, nocturnal plasma melatonin could be strongly suppressed with as little as 15 to 20 lux. Thus the method of light presentation may be more important than its absolute illuminance (lux) value in determining its biologic or therapeutic i&caC\'.
We did not predict that we would fInd different IeSpOn ses to withdrawal following treatment with the two different visors, however such a result has been �rted in at least one previous study of light therapy. Thus, Wirz-Justice et al. (1986) showed greater and more rapid relapse following withdrawal from a dim-than ma bright-light treatment. In reviewing the literature Light-Visor Treatment for SAD 159 on crossover studies of light therapy, we have noted lower baseline depression levels for the second treat ment condition when the less effective treatment fol lows the more effective one than when the order is reversed . This would suggest a greater carry-over effect following the more effective treatment. It is difficult to reconcile these earlier obser vations with those from the present study since treat ment with the bright visor, which was followed by less relapse than treatment with the dim visor, was not more effective.
In conclusion, the results of the present study offer controlled data on the efficacy of a novel light delivery system in a large number of SAD patients treated at three separate centers. Although both patients and cli nicians believed the visor to be a clinically effective treat ment, its true efficacy, as defIned by superiority to a control treatment, was not established. If it is not purely a placebo, then the apparent absence of a relationship between intensity and response, such as has been de scribed for earlier light-box treatment studies, has yet to be explained. It may emerge that the mode of pre sentation of light, not merely the intensity, is an important understudied area of light therapy.
